HC Wainwright Cuts Earnings Estimates for TG Therapeutics

Key Points

• HC Wainwright lowered its Q4 2026 EPS estimate for TG Therapeutics to $0.31 from $0.41, while keeping a Buy rating and a $77 price target on the stock.
• TG Therapeutics recently reported Q1 results that missed earnings expectations, posting $0.12 EPS versus the $0.23 estimate, though revenue came in slightly above forecasts at $204.92 million and rose 69.5% year over year.
• Analyst sentiment remains mixed but overall positive, with MarketBeat citing a Moderate Buy consensus and a $53.33 average target price, even as the stock traded down 3.7% to $55.01.

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Research analysts at HC Wainwright dropped their Q4 2026 earnings estimates for TG Therapeutics in a research report issued on Monday, July 13th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will post earnings per share of $0.31 for the quarter, down from their previous estimate of $0.41. HC Wainwright currently has a "Buy" rating and a $77.00 target price on the stock. The consensus estimate for TG Therapeutics' current full-year earnings is $1.51 per share. HC Wainwright also issued estimates for TG Therapeutics' FY2027 earnings at $2.32 EPS.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the prior year, the business earned $0.03 earnings per share. The business's revenue for the quarter was up 69.5% on a year-over-year basis.

Several other research analysts have also issued reports on the company. Zacks Research upgraded TG Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Monday, June 1st. Weiss Ratings upgraded TG Therapeutics from a "hold (c)" rating to a "hold (c+)" rating in a research report on Friday, May 1st. Jefferies Financial Group restated a "buy" rating and set a $83.00 target price on shares of TG Therapeutics in a research report on Monday, June 22nd. Finally, Bank of America lifted their price target on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an "underperform" rating in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $53.33.

TG Therapeutics Trading Down 3.7%

Shares of TGTX stock opened at $55.01 on Tuesday. The stock has a market cap of $8.42 billion, a price-to-earnings ratio of 19.23, a P/E/G ratio of 1.38 and a beta of 1.60. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $59.30. The firm has a fifty day moving average of $46.60 and a 200-day moving average of $36.52.

Institutional Trading of TG Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada boosted its stake in TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company's stock worth $2,985,000 after purchasing an additional 10,660 shares during the period. NewEdge Advisors LLC boosted its position in shares of TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company's stock worth $299,000 after buying an additional 665 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock worth $75,683,000 after buying an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of TG Therapeutics by 5.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company's stock worth $11,319,000 after buying an additional 14,689 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 573 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company's research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.